Polatuzumab Vedotin: First Global Approval

Drugs - United Kingdom
doi 10.1007/s40265-019-01175-0
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Correction To: Polatuzumab Vedotin: First Global Approval

Drugs
Pharmacology
2019English

Elagolix: First Global Approval

Drugs
Pharmacology
2018English

Correction To: Ibalizumab: First Global Approval

Drugs
Pharmacology
2018English

Erratum To: Brodalumab: First Global Approval

Drugs
Pharmacology
2016English

Correction To: Delafloxacin: First Global Approval

Drugs
Pharmacology
2018English

Correction To: Camrelizumab: First Global Approval

Drugs
Pharmacology
2019English

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2019English

First Tissue-Agnostic Drug Approval Issued

Cancer Discovery
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy